A Phase I Study to Evaluate the Safety and Preliminary Efficacy of [225Ac]Ac-DOTATATE Injection Combined With Tislelizumab in the Maintenance Treatment Period for Patients of Extensive-stage Small Cell Lung Cancer (ES-SCLC) With Somatostatin Receptors (SSTR)+ as First-line Treatment

This is a phase I study to evaluate the safety and preliminary efficacy of \[225Ac\]Ac-DOTATATE injection combined with tislelizumab in the maintenance treatment period for patients of extensive-stage small cell lung cancer (ES-SCLC) with somatostatin receptors (SSTR)+ as first-line treatment.Patients with ES-SCLC who have completed the induction therapy of first-line standard treatment and are yet to enter the maintenance treatment period are planned to be enrolled.

Trial Details

NCT ID
NCT07413042
Phase
PHASE1
Sponsor
Peking University Cancer Hospital & Institute
Status
RECRUITING
Cancer Type
Lung Cancer
Interventions
  • [225Ac]Ac-DOTATATE
Locations (sample)
  • Beijing, Beijing Municipality, China|39.9075,116.39723

Key Eligibility Criteria

  • Patients must have the ability to understand and sign an approved informed consent form (ICF).
  • Patients must be \>= 18 and \<＝80 years of age.
  • Extensive-stage small cell lung cancer that requires histopathological or cytological confirmation.
  • Presence of at least 1 measurable site of disease (based on RECIST 1.1).

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lung Cancer Trials on Trialify →